COVID-19 Severity Shifts the Cytokine Milieu Toward a Proinflammatory State in Egyptian Patients : A Cross-Sectional Study
Despite extensive research to decipher the immunological basis of coronavirus disease (COVID-19), limited evidence on immunological correlates of COVID-19 severity from MENA region and Egypt was reported. In a single-center cross-sectional study, we have analyzed 25 cytokines that are related to immunopathologic lung injury, cytokine storm, and coagulopathy in plasma samples from 78 hospitalized Egyptian COVID-19 patients in Tanta University Quarantine Hospital and 21 healthy control volunteers between April 2020 and September 2020. The enrolled patients were divided into 4 categories based on disease severity, namely mild, moderate, severe, and critically ill. Interestingly, interleukin (IL)-1-α, IL-2Rα, IL-6, IL-8, IL-18, tumor necrosis factor-alpha (TNF-α), FGF1, CCL2, and CXC10 levels were significantly altered in severe and/or critically ill patients. Moreover, principal component analysis (PCA) demonstrated that severe and critically ill COVID-19 patients cluster based on specific cytokine signatures that distinguish them from mild and moderate COVID-19 patients. Specifically, levels of IL-2Rα, IL-6, IL-10, IL-18, TNF-α, FGF1, and CXCL10 largely contribute to the observed differences between early and late stages of COVID-19 disease. Our PCA showed that the described immunological markers positively correlate with high D-dimer and C-reactive protein levels and inversely correlate with lymphocyte counts in severe and critically ill patients. These data suggest a disordered immune regulation, particularly in severe and critically ill Egyptian COVID-19 patients, manifested as overactivated innate immune and dysregulated T-helper1 responses. Additionally, our study emphasizes the importance of cytokine profiling to identify potentially predictive immunological signatures of COVID-19 disease severity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research - 43(2023), 6 vom: 01. Juni, Seite 257-268 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salem, Mohamed L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 12.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/jir.2023.0029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357549554 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357549554 | ||
| 003 | DE-627 | ||
| 005 | 20231227131304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/jir.2023.0029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM357549554 | ||
| 035 | |a (NLM)37252793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salem, Mohamed L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Severity Shifts the Cytokine Milieu Toward a Proinflammatory State in Egyptian Patients |b A Cross-Sectional Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 12.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite extensive research to decipher the immunological basis of coronavirus disease (COVID-19), limited evidence on immunological correlates of COVID-19 severity from MENA region and Egypt was reported. In a single-center cross-sectional study, we have analyzed 25 cytokines that are related to immunopathologic lung injury, cytokine storm, and coagulopathy in plasma samples from 78 hospitalized Egyptian COVID-19 patients in Tanta University Quarantine Hospital and 21 healthy control volunteers between April 2020 and September 2020. The enrolled patients were divided into 4 categories based on disease severity, namely mild, moderate, severe, and critically ill. Interestingly, interleukin (IL)-1-α, IL-2Rα, IL-6, IL-8, IL-18, tumor necrosis factor-alpha (TNF-α), FGF1, CCL2, and CXC10 levels were significantly altered in severe and/or critically ill patients. Moreover, principal component analysis (PCA) demonstrated that severe and critically ill COVID-19 patients cluster based on specific cytokine signatures that distinguish them from mild and moderate COVID-19 patients. Specifically, levels of IL-2Rα, IL-6, IL-10, IL-18, TNF-α, FGF1, and CXCL10 largely contribute to the observed differences between early and late stages of COVID-19 disease. Our PCA showed that the described immunological markers positively correlate with high D-dimer and C-reactive protein levels and inversely correlate with lymphocyte counts in severe and critically ill patients. These data suggest a disordered immune regulation, particularly in severe and critically ill Egyptian COVID-19 patients, manifested as overactivated innate immune and dysregulated T-helper1 responses. Additionally, our study emphasizes the importance of cytokine profiling to identify potentially predictive immunological signatures of COVID-19 disease severity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Egyptian COVID-19 patients | |
| 650 | 4 | |a Luminex assay | |
| 650 | 4 | |a coagulopathy | |
| 650 | 4 | |a cytokine profile | |
| 650 | 4 | |a proinflammatory cytokines | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-18 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-2 Receptor alpha Subunit |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 1 |2 NLM | |
| 650 | 7 | |a 104781-85-3 |2 NLM | |
| 700 | 1 | |a Eltoukhy, Madonna M |e verfasserin |4 aut | |
| 700 | 1 | |a Shalaby, Rasha E |e verfasserin |4 aut | |
| 700 | 1 | |a Okasha, Kamal M |e verfasserin |4 aut | |
| 700 | 1 | |a El-Shanshoury, Mohamed R |e verfasserin |4 aut | |
| 700 | 1 | |a Attia, Mohamed A |e verfasserin |4 aut | |
| 700 | 1 | |a Hantera, Mohamed S |e verfasserin |4 aut | |
| 700 | 1 | |a Hilal, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a Eid, Mohammed A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research |d 1995 |g 43(2023), 6 vom: 01. Juni, Seite 257-268 |w (DE-627)NLM075191857 |x 1557-7465 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:257-268 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/jir.2023.0029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 6 |b 01 |c 06 |h 257-268 | ||